Stay updated on Nivolumab Combo in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Multiple Myeloma Clinical Trial page.

Latest updates to the Nivolumab Combo in Multiple Myeloma Clinical Trial page
- CheckyesterdayChange DetectedThe topics section no longer includes 'Multiple Myeloma' and the related topic 'MedlinePlus Genetics'. This may affect navigation and discovery of the study by disease and genetics-related topics.SummaryDifference0.1%

- Check8 days agoChange DetectedThe Results section has been added, detailing primary and secondary outcomes such as progression-free survival, overall survival, ORR, time to response, and duration of response.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAdded a MedlinePlus Genetics topic covering Multiple myeloma, expanding core content and proper noun coverage.SummaryDifference0.2%

- Check36 days agoChange Detected- Added a government funding notice and current operating status guidance; clarified that the NIH Clinical Center is open; updated the version to v3.2.0. - Removed the older topic reference to MedlinePlus Genetics: Multiple myeloma and old revision tag v3.1.0.SummaryDifference3%

- Check44 days agoChange DetectedUpdate to include MedlinePlus Genetics topic on Multiple myeloma and bump to v3.1.0; remove the older term Plasma cell myeloma and revert to v3.1.0 terminology.SummaryDifference0.4%

- Check51 days agoChange DetectedRemoved MedlinePlus Genetics content related to multiple myeloma, resulting in less genetics-specific information about the disease on the page.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Combo in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Multiple Myeloma Clinical Trial page.